Steven Fletcher

4.0k citations

110 papers · 3.3k indexed · h-index 35

Organic Chemistry top 2%
Oncology top 5%
- Cytokine Signaling Pathways and Interactions 14
Toxicology top 2%
Molecular Biology top 5%
- Chemical Synthesis and Analysis 20
- Protein Degradation and Inhibitors 17
- Cell death mechanisms and regulation 14
- Ubiquitin and proteasome pathways 12
- Histone Deacetylase Inhibitors Research 11
- RNA Interference and Gene Delivery 10
Hematology top 5%
- Multiple Myeloma Research and Treatments 10

Co-authors: Patrick T. Gunning Andrew D. Hamilton Edward V. Prochownik Jeremy L. Yap James Turkson Lijia Chen Maryanna E. Lanning Jay Chauhan
Cited by: Organic Chemistry Oncology Toxicology
Journals: Angewandte Chemie International Edition (2 papers)Blood (1 paper)Biomaterials (1 paper)
Partner nations: United States Canada United Kingdom

In The Last Decade

Steven Fletcher

105 papers receiving 3.3k citations

Peers

Countries citing papers authored by Steven Fletcher

Since Specialization

Citations

This map shows the geographic impact of Steven Fletcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Fletcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Fletcher more than expected).

Fields of papers citing papers by Steven Fletcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Fletcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Fletcher. The network helps show where Steven Fletcher may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Steven Fletcher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Fletcher Line = papers co-authored together Steven Fletcher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors European Journal of Medicinal Chemistry ·Christopher C. Goodis,Christian Eberly,Alexandria M. Chan,Minjung Kim,Brandon D. Lowe,Curt I. Civin,Steven Fletcher	2024	4
2	First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties Journal of Pharmacology and Experimental Therapeutics ·Mohan E. Tulapurkar,Kari Ann Shirey,Katerina N. Lugkey,Wendy Luo,Ritu Lal,Adam Galan,Omar Mahmoud,Nathaniel McClean,Kiruphagaran Thangaraju,Daniel Cericola,Daniel R. Lewis,William A. Murphy,Steven Fletcher,Alexander D. MacKerell,Stefanie N. Vogel,Paul R. Shapiro,Jeffrey D. Hasday	2024	2
3	Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation Bioengineering & Translational Medicine ·Nhu Truong,Andrea L. Cottingham,Shruti Dharmaraj,Jacob R. Shaw,Jackline Joy Lasola,Christopher C. Goodis,Steven Fletcher,Ryan M. Pearson	2023	6
4	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival Clinical Cancer Research ·Francesca Fontana,Michael J. Scott,John S. Allen,Xiaoxia Yang,Grace Cui,Dipanjan Pan,Noriko Yanaba,Mark A. Fiala,Julie O’Neal,Anne H. Schmieder-Atteberry,Julie Ritchey,Michael P. Rettig,Kathleen Simons,Steven Fletcher,Ravi Vij,John F. DiPersio,Gregory M. Lanza	2020	19
5	Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer Theranostics ·Alison K. Esser,Michael H. Ross,Francesca Fontana,Xinming Su,Ariel Gabay,Gregory C. Fox,Yalin Xu,Jingyu Xiang,Anne H. Schmieder,Xiaoxia Yang,Grace Cui,Michael J. Scott,Samuel Achilefu,Jay Chauhan,Steven Fletcher,Gregory M. Lanza,Katherine N. Weilbaecher	2020	31
6	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors Clinical Cancer Research ·Aslamuzzaman Kazi,Shengyan Xiang,Hua Yang,Liwei Chen,Perry Kennedy,Muhammad Ayaz,Steven Fletcher,Christopher T. Cummings,Harshani R. Lawrence,Francisca Beato,Ya’an Kang,Michael P. Kim,Andrea E. Delitto,Patrick W. Underwood,Jason B. Fleming,José G. Treviño,Andrew D. Hamilton,Saı̈d M. Sebti	2019	53
7	Optimization of a small-molecule Lipid II binder Bioorganic & Medicinal Chemistry Letters ·Jay Chauhan,Steven M. Kwasny,Steven Fletcher,Timothy J. Opperman,Erik P. H. de Leeuw	2019	0
8	Discovery and lead identification of quinazoline-based BRD4 inhibitors Bioorganic & Medicinal Chemistry Letters ·Shyh‐Ming Yang,Daniel J. Urban,Makoto Yoshioka,Jeffrey Strovel,Steven Fletcher,Amy Q. Wang,Xin Xu,Pranav Shah,Xin Hu,Matthew D. Hall,Ajit Jadhav,David J. Maloney	2018	13
9	Discovery of Mcl-1 inhibitors based on a thiazolidine-2,4-dione scaffold Bioorganic & Medicinal Chemistry Letters ·E. E. Whiting,Mithun Raje,Jay Chauhan,Paul T. Wilder,Daniel Van Eker,Samuel Hughes,Nathan G. Bowen,Gregory E.A. Vickers,Ian C. Fenimore,Steven Fletcher	2017	15
10	A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors Journal of Biological Methods ·Huabo Wang,Anand Ramakrishnan,Steven Fletcher,Edward V. Prochownik	2015	17
11	Small-molecule inhibitors of the Myc oncoprotein Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms ·Steven Fletcher,Edward V. Prochownik	2014	120
12	The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition BMC Cancer ·Chander Peddaboina,Daniel C. Jupiter,Steven Fletcher,Jeremy L. Yap,Arun Rai,Richard P. Tobin,Weihua Jiang,Philip A. Rascoe,M Karen Newell Rogers,W. Roy Smythe,Xiaobo Cao	2012	70
13	Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors Organic & Biomolecular Chemistry ·Jeremy L. Yap,Xiaobo Cao,Kenno Vanommeslaeghe,Kwan‐Young Jung,Chander Peddaboina,Paul T. Wilder,Anjan Nan,Alexander D. MacKerell,W. Roy Smythe,Steven Fletcher	2012	54
14	An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery Biomaterials ·Rajendra Narayan Mitra,Mona Doshi,Xiaolei Zhang,Jessica C. Tyus,Niclas E. Bengtsson,Steven Fletcher,Brent D. G. Page,James Turkson,Andre J. Gesquiere,Patrick T. Gunning,Glenn A. Walter,Swadeshmukul Santra	2011	48
15	Disruption of Transcriptionally Active Stat3 Dimers with Non‐phosphorylated, Salicylic Acid‐Based Small Molecules: Potent in vitro and Tumor Cell Activities ChemBioChem ·Steven Fletcher,Jardeep Singh,Xiaolei Zhang,Peibin Yue,Brent D. G. Page,Sumaiya Sharmeen,Vijay Shahani,Wei Zhao,Aaron D. Schimmer,James Turkson,Patrick T. Gunning	2009	70
16	A Photostable, pH-Invariant Fluorescein Derivative for Single-Molecule Microscopy Journal of Fluorescence ·Baoxu Liu,Steven Fletcher,Miriam Avadisian,Patrick T. Gunning,Claudiu C. Gradinaru	2009	30
17	Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein ChemMedChem ·Steven Fletcher,James Turkson,Patrick T. Gunning	2008	88
18	Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques Current Topics in Medicinal Chemistry ·Steven Fletcher,Andrew Hamilton	2007	54
19	Recognition of solvent exposed protein surfaces using anthracene derived receptors Organic & Biomolecular Chemistry ·Andrew J. Wilson,Jason Hong,Steven Fletcher,Andrew D. Hamilton	2006	31
20	Protein surface recognition and proteomimetics: mimics of protein surface structure and function Current Opinion in Chemical Biology ·Steven Fletcher,Andrew D. Hamilton	2005	103

About Steven Fletcher

Steven Fletcher is a scholar working on Toxicology, Molecular Biology and Organic Chemistry, having authored 110 papers that have together received 3.3k indexed citations. Recurring topics across this work include Chemical Synthesis and Analysis (20 papers), Protein Degradation and Inhibitors (17 papers), Cell death mechanisms and regulation (14 papers), Cytokine Signaling Pathways and Interactions (14 papers), Ubiquitin and proteasome pathways (12 papers), Histone Deacetylase Inhibitors Research (11 papers), Multiple Myeloma Research and Treatments (10 papers) and RNA Interference and Gene Delivery (10 papers). The work is most often cited by research in Organic Chemistry (1.1k citations), Oncology (980 citations) and Toxicology (120 citations). Steven Fletcher has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Patrick T. Gunning, Andrew D. Hamilton, Edward V. Prochownik, Jeremy L. Yap, James Turkson, Lijia Chen, Maryanna E. Lanning, Jay Chauhan, Peibin Yue and Xiaolei Zhang. Their work appears in journals such as Angewandte Chemie International Edition, Blood and Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact